John M. Lee

Pharmaceutical development of IPI‐504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer

Denise A. Mayes, G. Sylvester, J. Adams, 2010 .

Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of 17-AAG and Potent Inhibitor of Hsp90

G. Sylvester, E. Holson, J. Helble, 2008 .

A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

R. Ramlau, I. Láng, M. Liao, 2021, Cancer Chemotherapy and Pharmacology.

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

Jeanne A. Ferguson, J. Sydor, J. Adams, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

153 POSTER IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class

J. Sydor, E. Holson, L. Grenier, 2008 .

Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.

K. West, J. Ge, J. R. Porter, 2009, Current topics in medicinal chemistry.